Plain language summary
SCLC highlights from ASCO 2026
Short summaries of key small-cell lung cancer treatment trials presented at the 2026 ASCO Annual Meeting
What is it about?
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, researchers shared new findings that may influence future management strategies for small-cell lung cancer (SCLC), a highly aggressive malignancy associated with rapid progression and poor survival outcomes. Despite initial responses to treatment, relapse is common, and effective second-line options remain limited.
The DeLLphi-304 trial explored treatment outcomes in patients with SCLC and baseline brain metastases. It evaluated intracranial efficacy compared with chemotherapy, aiming to improve disease control and survival in patients with central nervous system involvement.
Additional real-world data examined second-line treatment patterns following first-line chemoimmunotherapy in extensive-stage SCLC. These analyses assessed how platinum sensitivity influences outcomes and whether commonly used treatment approaches provide meaningful clinical benefit. Further data evaluated the continuation of checkpoint inhibitor therapy beyond the first line, investigating its impact on progression-free and overall survival in the second-line setting.
Why is it important?
Improving outcomes in relapsed SCLC and identifying effective treatment strategies beyond the first line remain key challenges in disease management. Data presented at ASCO 2026 provide evidence that may help inform treatment selection and sequencing.
The DeLLphi-304 trial showed improved central nervous system progression-free survival and overall survival, alongside higher intracranial response rates compared with chemotherapy. Brain metastases are associated with poor prognosis, and improved intracranial control may help address a key unmet need in this population.
Real-world analyses demonstrated that outcomes vary according to platinum sensitivity, with poorer survival observed in patients with platinum-refractory disease. These findings reinforce the importance of patient stratification when selecting a second-line treatment.
Data on the continuation of checkpoint inhibitor therapy in the second-line setting showed no association with improved progression-free or overall survival, highlighting limitations of existing approaches and the need for more effective therapies.
Key takeaways: • Improving outcomes in SCLC with brain metastases remains a key unmet need • Intracranial efficacy is an important consideration in treatment selection • Platinum sensitivity continues to influence second-line outcomes • Continuation of checkpoint inhibitors beyond the first line may not improve survival • There is a continued need for more effective second-line SCLC therapies
